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A B S T R A C T
Clinical characteristics of the cohort of 150 patients with inflammatory bowel diseases, ulcerative colitis (UC) and
Crohn's disease (CD), Vukovarsko-Srijemska County, Croatia, were retrospectively assessed. UC was clinically presented
with frequent passage of bloody, slimy stools, while preferential symptoms of CD were fever, anemia and severe weight
loss, differences reflecting longer duration of symptoms prior to the diagnosis, in patients with CD. The prevalent disease
localisations, in patients with UC, were the rectum and the left colon and the anorectum, while the prevailing phenotype,
in patients with CD, corresponded with younger adult age at disease onset, ileocolonic localization and stricturing dis-
ease behavior. Intestinal complications, including perforation, fistula, abscess and ileus, were more prevalent in patients
with CD. Of extraintestinal complications, only ankylosing spondylitis and erythema nodosum, reached marginally sig-
nificant differences, in favor to patients with CD. Shortcomings of this study include the lack of associations and the
time-dependent disease projections.
Key words: inflammatory bowel diseases, Crohn's disease, ulcerative colitis, symptoms, phenotypes, complications, a
cross-sectional cohort study, North-Eastern Croatia
Introduction
Ulcerative colitis (UC) and Crohn's disease (CD) are
chronic intestinal conditions with common pathogenetic
background and similar clinical expression, termed in-
flammatory bowel diseases (IBD)1.
IBD mostly occur in adolescents and young adults and
continue in a chronic manner. CD typically involves ter-
minal ileum and the ascending colon, but can affect any
part of the gastrointestinal tract, respecting a segmental,
discontinuous form of spreading. In CD, inflammation
may break throughout the wall, forming the granulomas,
which later in the disease can be associated with the in-
testinal strictures and fistulas and the requirement for a
surgical treatment1,2. UC involves the rectum and may
spread to the colon, in an uninterrupted manner, some-
times affecting the entire colon. In UC, inflammation is
localized in the mucosa and this is the reason why UC is
not associated with the late surgical complications. How-
ever, in the case of severe bleeding, bloating, or a failure
of the patient to respond to the medical treatment, sur-
gery may be considered, by means of colectomy. Patients
with UC are also at increased risk of colon cancer3,4.
Both diseases are clinically presented with persistent
diarrhea, hemorrhage and abdominal pain, and when the
disease is severe, or of a long duration, also with weight
loss, malnutrition and fever1. The symptoms tend to ap-
pear in flare-ups, with remissions in between. Due to
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chronic inflammation and the permanent activation of
the immune system, in both diseases, a number of extra-
intestinal complications can also appear, most of them
being immunologically mediated, such as skin lesions,
joint pain, eye inflammation and liver disorders3.
According to these clinical characteristics, IBD is pro-
minently a disabilitating disorder. Medical treatment is
based on using drugs with antiinflammatory properties,
including aminosalicylates, steroids, immune modifiers,
antibiotics and biologic treatment (infliximab)5. Although
there is evidence that these available therapeutic options
have modified the natural history of IBD, they are not
completely successful to provide the cure and relief from
the long-lasting complications. There is an interest, the-
refore, within both, the research and the public commu-
nities, to gain insights into the causes of these diseases,
to allow primary prevention and targeted therapy5.
Many potential causing factors, for IBD, have been
proposed to date6,7. Increasing evidence suggests IBD as
complex, polygenic disorders with incomplete genetic
penetrance and poor genotype-phenotype correlation8.
Rapid changes in the epidemiologic pattern of these dis-
eases, during the past decades, in Europe and wider in
the world, provide the evidence that changes in lifestyles
and environmental exposures are those dominant factors
that drive clinical expression and the natural history of
these diseases, while the genetic factors, although nowa-
days in the focus of research, have only permissive role8,9.
There is an initiative, in the scientific community, to con-
duct long-term studies, in order to compare changes in
environmental factors and treatment options with chan-
ges in the natural course and prognosis of IBD4,5. Stan-
dardization of the severity and the extension of a disease,
necessary to making these comparisons, has recently
been provided in the form of the Montreal’s classification
of IBD10.
Aims
The second aim of the epidemiologic study, conducted
in Vukovarsko-Srijemska County, continental Croatia,
2010 (see the paper entitled »Incidence and prevalence of
inflammatory bowel disease in Vukovarsko-Srijemska
County, Croatia, 1991–2000 and 2001–2010: a popula-
tion-based study«), was to analyze clinical features of the
cohort group of 150 patients with IBD, 119 with UC and
31 with CD, including information on: 1) symptoms and
their duration at the first medical check up, taken sepa-
rately for each of the two diagnoses, 2) the distribution of
phenotypes, for both diseases, classified according to the
Montreal’s classification of IBD and 3) intestinal and
extraintestinal complications.
Subjects and Methods
Data on subjects and methods are identical, as those
ones already described in the paper entitled »Incidence
and prevalence of inflammatory bowel disease in Vuko-
varsko-Srijemska County, Croatia, 1991–2000 and 2001–
2010: a population-based study« (see page).
Statistical analysis
Descriptive statistics (expressed with absolute num-
bers of patients and percentages) were used to analyze
the presence/absence of symptoms and complications, de-
pending on the type of diagnosis. Differences among the
categories were assessed by using the ÷2 and Fisher exact
tests. The duration of the symptoms prior to the first
medical check up (in months) was analyzed by using the
nonparametric Mann-Whitney U-test. Distributions of
phenotypes, particularly for UC and CD, were repre-
sented graphically, as columns of percentages. The ex-
tent of CD, according to the Montreal’s classification
(three stages per each of three categories: age at time of
diagnosis, location and behavior, Table 7), was repre-
sented by using descriptive statistics (absolute numbers
of patients and percentages), while differences among
categories were analyzed by using ÷2-test.
In relation to UC, the Montreal's classification defines
three phenotypes with respect to the extent of the dis-
ease and three severity stages (in addition to the stage
»clinical remission«). In relation to CD, three categories
of age at diagnosis, disease localization and behavior, are
defined10.
Results
Table 1 shows symptoms at the time of diagnosis and
their distribution between two patient groups, one diag-
nosed with UC and the other diagnosed with CD. Signifi-
cant difference was found in four symptoms, including:
blood and slime in stool, stool frequency, fever and
weight loss. Bloody and slimy stool was more typical for
UC, with the number of stools per day exceeding four. Fe-
ver and severe weight loss (more than 10 kg), in the last
three months, were more prominently present in pa-
tients with CD, although the latter symptom might be
the result of the bias, due to the small number of patients
in the group diagnosed with CD.
Duration of symptoms prior to the diagnosis was sig-
nificantly longer in patients with CD (median around six
months, with a quarter of patients having symptoms lon-
ger then a year) (Mann-Whitney U-test) (Figure 1). Me-
dian value for patients with the diagnosis of UC was
around three months; a half of patients had symptoms
duration between two and seven months (Figure 1).
Figure 2 shows distribution of phenotypes, in relation
to the extent of the disease, in patients with UC, as de-
fined according to the Montreal’s classification. Although
the results did not reach the significance level (p=0.171,
c2-test), the phenotype presented with the maximum
percentage of patients, 41.18%, was the phenotype E2
(left sided colitis, involving the colorectum). The pheno-
type E1 (proctitis), was at the second position, with
36.13%, and the phenotype E3 (extensive, pancolitis) – at
the third position, with 22.69%.
In patients diagnosed with CD, the most frequent
phenotype, according to the Montreal’s classification, al-
though the results were not statistically significant, was
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the phenotype A2L3B3 (younger adult age at disease on-
set, ileocolonic localization, penetrating behavior) (p=
0.117, c2-test) (Figure 3).
Distribution of the three defined categories, according
to the age, localization and the disease behavior, showed
a significantly higher proportion of patients with the
ileocolonic localization of the disease (L3), without any
preference under the categories age and behavior (p=
0.026, c2-test) (Table 2). However, the category 2 of age
(age between 17 and 40 y at the onset of the disease) and
the category 2 of behavior (stricturing) had a higher per-
centage of patients, in comparison to the rest two.
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TABLE 1
SYMPTOMS AT THE TIME OF DIAGNOSIS, FOR ULCERATIVE










Yes 55 (46.2) 22 (71.0)
0.014*
No 64 (53.8) 9 (29.0)
Abdominal pain
Yes 84 (70.6) 26 (83.9)
0.136*
No 35 (29.4) 5 (16.1)
Bloody and slimy stool
Yes 114 (95.8) 17 (54.8)
<0.001†
No 5 (4.2) 14 (45.2)
The number of stools per day
<1 0 (0) 2 (6.5)
0.046†
1–3 19 (16.0) 8 (25.8)
4–7 52 (43.7) 11 (35.5)
>8 48 (40.3) 10 (32.3)
Fatigue
Yes 76 (63.9) 23 (74.2)
0.280*
No 43 (36.1) 8 (25.8)
Fever
Yes 28 (23.5) 15 (48.4)
0.006*
No 91 (76.5) 16 (51.6)
Joint pain
Yes 36 (30.3) 11 (35.5)
0.576*
No 83 (69.7) 20 (64.5)
Weight loss (kg) in the last three months
Without loss 28 (23.5) 1 (3.2)
0.002*
1–2 12 (10.1) 3 (9.7)
3–5 24 (20.2) 3 (9.7)
6–9 25 (21.0) 5 (16.1)
>10 30 (25.2) 19 (61.3)
Total 119 (100) 31 (100)




































Fig. 1. Symptoms duration at the time of diagnosis (p=0.001;
Mann-Whitneyjev U-test).
Fig. 2. Distribution of patients with ulcerative colitis (UC) ac-
cording to the phenotypes (Montreal's classification).
Fig. 3. Distribution of patients with Crohn’s disease (CD) accord-
ing to the phenotypes (Montreal's classification).
TABLE 2
THE EXTENT OF A DISEASE, FOR CROHN'S DISEASE,
DEPENDING ON THE PHENOTYPES
Phenotype 1 2 3 p
A 4 (13) 18 (58) 9 (29) 0.087*
L 8 (26) 3 (10) 20 (64) 0.026*
B 8 (29) 18 (64) 5 (16) 0.125*
* – c2-test
Analysis of the intestinal complications, between two
patient groups, showed significantly higher participation
of complications in patients diagnosed with CD, then in
those diagnosed with UC, including perforation, fistula,
abscess and ileus (Table 3). There were no significant dif-
ferences, between the groups, with respect to extra-
intestinal complications, except the tendency for the as-
sociation between CD and Ankylosing spondylitis and
Erythema nodosum (p=0.057 and 0.085, respectively,
Fisher’s exact test).
When distributions of intestinal and extraintestinal
complications were tested according to the sex (Males/Fe-
males), without preferences with respect to the specific
diagnosis of IBD, significant results were obtained for
the association between the female sex and massive rec-
tal bleeding (Table 5) (p=0.044, c2-test).
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TABLE 3
INTESTINAL COMPLICATIONS, DISTRIBUTED BETWEEN THE










Yes 13 (10.9) 2 (6.5)
0.737*
No 106 (89.1) 29 (93.5)
Toxic megacolon
Yes 3 (2.5) 0 (0)
>0.950*
No 116 (97.5) 31 (100)
Intestinal perforation
Yes 1 (0.8) 3 (9.7)
0.028*
No 118 (99.2) 28 (90.3)
Carcinoma
Yes 0 (0) 1 (3.2)
0.207*
No 119 (100) 30 (96.8)
Fistula
Yes 1 (0.8) 7 (22.6)
<0.001*
No 118 (99.2) 24 (77.4)
Abscess
Yes 1 (0.8) 9 (29.0)
<0.001*
No 118 (99.2) 22 (71.0)
Ileus
Yes 1 (0.8) 8 (25.8)
<0.001*
No 118 (99.2) 23 (74.2)
Total 119 (100) 31 (100)
* – Fisher’s exact test
TABLE 4
EXTRAINTESTINAL COMPLICATIONS, DISTRIBUTED BETWEEN











Yes 24 (20.2) 8 (25.8)
0.495*
No 95 (79.8) 23 (74.2)
Sacroiliitis
Yes 3 (2.5) 3 (9.7)
0.103†
No 116 (97.5) 28 (90.3)
Ankylosing spondylitis
Yes 4 (3.4) 4 (12.9)
0.057†
No 115 (96.6) 27 (87.1)
Erythema nodosum
Yes 9 (7.6) 6 (19.4)
0.085†
No 110 (92.4) 25 (80.6)
Pyoderma gangrenosum
Yes 3 (2.5) 0 (0)
>0.950†
No 116 (97.5) 31 (100)
Skin vasculitis
Yes 0 (0) 1 (3.2)
0.207†
No 119 (100) 30 (96.8)
Aphtous stomatitis
Yes 29 (24.4) 9 (29.0)
0.595*
No 90 (75.6) 22 (71.0)
Gallstones
Yes 18 (15.1) 6 (19.4)
0.586†
No 101 (84.9) 25 (80.6)
Renal stones
Yes 15 (12.6) 2 (6.5)
0.526†
No 104 (87.4) 29 (93.5)
Uveitis
Yes 0 (0) 1 (3.2)
0.207†
No 119 (100) 30 (96.8)
Episcleritis, conjunctivitis
Yes 12 (10.1) 2 (6.5)
0.735†
No 107 (89.9) 29 (93.5)
Liver fatty infiltration
Yes 0 (0) 1 (3.2)
0.207†
No 119 (100) 30 (96.8)
Primary sclerosing cholangitis
Yes 1 (0.8) 1 (3.2)
0.372†
No 118 (99.2) 30 (96.8)
Thromboembolic events
Yes 1 (0.8) 0 (0)
>0.950†
No 118 (99.2) 31 (100)
Amyloidosis
Yes 0 (0) 0 (0)
>0.950†
No 119 (100) 31 (100)
Total 119 (100) 31 (100)
* – c2-test, † – Fisher’s exact test
Discussion
Discussion on symptoms at the time of diagnosis
Both IBD entities, UC and CD, in the early time-
-course of disease, may present with the same symptoms,
including diarrhea and abdominal pain. Moreover, these
symptoms may overlap with a functional intestinal disor-
der, called irritable bowel syndrome (IBS). This may be
the reason of a delay in the exact diagnosis of IBD. The
difficulties with at time diagnosis of IBD are also associ-
ated with the need for the invasive technique, colono-
scopy, presently available to making the initial diagnosis.
The question, a clinician is faced with, is when is it the
right time to recommend colonoscopy11. Early diagnosis
confirmation is, however, essential for effective treat-
ments, especially important in the case of CD, where the
severity of disease and a predisposition for penetrat-
ing/stricturing disorders is a function of disease dura-
tion5,12.
According to our results, there was a significant dif-
ference between patients with UC and CD, in prevalence
of symptoms at the time of diagnosis. Bloody and slimy
stools, with frequent loose stool (>4 per day), was a typi-
cal clinical presentation of patients with UC (p<0.001
and p=0.046, respectively, Fisher`s exact test) (Table 1).
Fever, anemia and severe weight loss (more then 10 kg in
the past three months), were more prominent symptoms
in patients with CD (Table 1). Fever was not specific
enough for CD, as there was the equivalent percentage of
patients with this diagnosis not having fever (Table 1).
These differences in clinical presentation of two dis-
eases might be reflective of a significant difference in
symptoms duration prior to the diagnosis (Figure 1). In
this regard, due to localization of the pathologic process
in the ileum, clinical presentation of CD may not be so
expressive, as it is in the case of UC, where inflammation
affects the outgoing part of the gastrointestinal tract,
that is, the colorectum. More clear symptoms, suspected
on CD, do not appear unless CD is in advanced stage of
the pathologic process, presenting, e.g. (as our results
also show), with anemia and weight loss (Table 1)11. In
this sense, our results also indicate a longer symptoms
duration prior to the diagnosis in patients with CD (me-
dian 6 months), then in patients with UC (median 3
months) (Figure 1). Moreover, even a quarter of patients
with CD have been conscious of the symptoms over a
year before the diagnosis (Figure 1). For clinicians, it
could be of importance to develop an early, non-invasive
risk prediction tool, to search for high risk patients for
IBD and, in particular, for CD, who might be candidates
for the invasive diagnostics. Some efforts have already
been taken, by adding new biologic and genetic markers,
to the clinical manifestations of IBD13.
Another potential reason of these differences in symp-
toms between two patient groups in our sample, might
be a higher proportion of males, among patients with CD
(M/F, 64.5%/35.5%), that is opposite to what is generally
cited in the literature1. We can speculate that younger
men may contact doctor later in the course of the disease,
as being less sensitive, then females, on insufficiently de-
fined sensations coming from their stomach. Or, there
can be a difference in clinical presentation of CD, or IBD
in general, between men and women. In favor to the lat-
ter presumption, our results on intestinal complications
indicated that one symptom, massive rectal bleeding, had
the sex preference, showing an association with the fe-
male sex (Table 5). In contrast, the literature citations
indicate that the problem of a delay in diagnosis of IBD,
and especially of CD, is present elsewhere; so, the issue of
an early diagnosis of IBD remains as a challenge for the
future11.
Discussion on phenotypes
The recent clinical classification of IBD, including
both, UC and CD, has been provided by the Montreal`s
classification10. The clinical usefulness includes the pos-
sibility to assess the prognosis and to choose more appro-
priate therapeutic options. The benefit provided to the
basic science includes better understanding the patho-
physiology of the different clinical manifestations of IBD.
The progress in knowledge on serologic and genetic mar-
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TABLE 5









Yes 4 (5.2) 11 (15.1)
0.044*
No 73 (94.8) 62 (84.9)
Toxic megacolon
Yes 1 (1.3) 2 (2.7)
0.613†
No 76 (98.7) 71 (97.3)
Intestinal perforation
Yes 2 (2.6) 2 (2.7)
>0.950†
No 75 (97.4) 71 (97.3)
Carcinoma
Yes 1 (1.3) 0 (0)
>0.950†
No 76 (98.7) 73 (100)
Fistula
Yes 3 (3.9) 5 (6.8)
0.486†
No 74 (96.1) 68 (93.2)
Abscess
Yes 5 (6.5) 5 (6.8)
>0.950†
No 72 (93.5) 68 (93.2)
Ileus
Yes 6 (7.8) 3 (4.1)
0.496†
No 71 (92.2) 70 (95.9)
Total 77 (100) 73 (100)
* – c2-test, † – Fisher’s exact test
kers, has also been considered, with the potential to
subclassify disease and to make projections for further
research8,10.
With respect to the extent of UC, our results indicate
that the most prominent phenotype, in our sample, is lo-
calization of disease in the rectum and the left colon
(phenotype E2, according to the Montreal`s classifica-
tion), with 41% of patients, then follows the phenotype
E1 (proctitis), with 36% of patients, and at the third posi-
tion is the extensive type of disease (proximal to the
splenic flexure), including also pancolitis (phenotype
E3), with 23% of patients (Figure 2). Since this distribu-
tion has not reached the statistically significant level, the
results cannot be strictly compared with the results ob-
tained in other cohort populations14. For example, in the
prospective Norwegian study, patients were equally dis-
tributed, that means, one third of patients per each
localisation15. To make a fairly good comparison between
different studies, with respect to the extent of disease, in-
formation on disease duration will also be needed, as the
proximal extent of inflammation has a tendency to prog-
ress over time12. Data collected in previous studies sug-
gest an increase over 50% in cumulative prevalence of
patients with pancolitis, after 20 years of disease dura-
tion16.
According to the Montreal`s classification, in addition
to data on the extent of disease, information on severity
of symptoms and disease activity, at the time of diagno-
sis, are also important (see the Methods), to serve as pre-
dictors of colectomy, or as the basis to planning immuno-
modulating, or biologic therapy, if disease is properly
severe10. In this context, analysis of symptoms, in this
study, showed that a passage of more than four bloody,
slimy stools per day, is the best way to describe the clini-
cal characteristics of the patients in the sample, corre-
sponding with the severity stage S2 (moderate) (see the
Methods). However, much of our knowledge does not yet
provide clear-cut answers; so this is the severity of the
initial disease which cannot indicate prognosis, because
the disease activity tends to decrease over time17,18.
When analysis of phenotypes of CD was made, the re-
sults showed the class age 17–40 y as the prevalent age at
disease onset (phenotype A2, according to the Montreal's
classification), with 58% of patients, the ileocolon as the
predominant disease localization (phenotype L3), with
64% of patients, and stricturing complication as the dom-
inant disease behavior (phenotype B3), with 64% of pa-
tients (Table 2). Altogether, from these results, the most
prevalent integrated phenotype in the sample, A2L3B3,
has arisen, presented with 22.58% of patients (Figure 3).
Systematic review data also indicate the prevalent par-
ticipation of the ileocolonic disease at the time of diagno-
sis, compared to isolated small bowel disease and pure co-
lonic disease12,19.
The results of the previous studies have taught us
that the localization of CD maintains relatively stable
over the course of the disease. In contrast, the disease be-
havior is more susceptible to changes with increasing dis-
ease duration12,20. For this reason, prospective studies,












Yes 13 (16.9) 19 (26.0)
0.172*
No 64 (83.1) 54 (74.0)
Sacroiliitis
Yes 4 (5.2) 2 (2.7)
0.682†
No 73 (94.8) 71 (97.3)
Ankylosing spondylitis
Yes 5 (6.5) 3 (4.1)
0.720†
No 72 (93.5) 70 (95.9)
Erithema nodosum
Yes 7 (9.1) 8 (11.0)
0.703*
No 70 (90.9) 65 (89.0)
Pyoderma gangrenosum
Yes 2 (2.6) 1 (1.4)
>0.950†
No 75 (97.4) 72 (98.6)
Skin vasculitis
Yes 0 (0) 1 (1.4)
0.487†
No 77 (100) 72 (98.6)
Aphtous stomatitis
Yes 18 (23.4) 20 (27.4)
0.571*
No 59 (76.6) 53 (72.6)
Gallstones
Yes 8 (10,4) 16 (21.9)
0.054*
No 69 (89.6) 57 (78.1)
Renal stones
Yes 12 (15.6) 5 (6.8)
0.092*
No 65 (84.4) 68 (93.2)
Uveitis
Yes 0 (0) 1 (1.4)
0.487†
No 77 (100) 72 (98.6)
Episcleritis, conjunctivitis
Yes 9 (11.7) 5 (6.8)
0.309*
No 68 (88.3) 68 (93.2)
Liver fatty infiltration
Yes 1 (1.3) 0 (0)
>0.950†
No 76 (98.7) 73 (100)
Primary sclerosing cholangitis
Yes 2 (2.6) 0 (0)
0.497†
No 75 (97.4) 73 (96.8)
Thromboembolic events
Yes 0 (0) 1 (1.4)
0.487†
No 77 (100) 72 (98.6)
Amyloidosis
Yes 0 (0) 0 (0)
>0.950†
No 77 (100) 73 (100)
Total 77 (100) 73 (100)
* – c2-test, † – Fisher’s exact test
with a long time of follow-up, have advantages over the
cross-sectional and retrospective ones4,14. Results of the
early studies indicated three types of CD behaviors, in-
cluding penetrating, stricturing and nonpenetrating/
nonstricturing (inflammatory), in addition to perianal
disease10. At the time of diagnosis, the inflammatory
form predominates (corresponding with symptoms such
as fever, anemia and weight loss) and the risk of compli-
cations (development of strictures or fistulas) increases
with the time of follow-up12,20. In the Olmsted County
population, Minnesota, USA, the 20-year cumulative ra-
te of all complications counted more than 60%21. Accord-
ing to the Norwegian prospective study, 53% of patients
developed stricturing or penetrating disease at 10 years
of follow-up15.
Also important, from the prognostic perspective, is
the fact that disease localization influences its evolution,
with ileal disease being more often stricturing and co-
lonic and ileocolonic disease – more often penetrating. In
addition, colonic disease remains uncomplicated for ma-
ny years, while small bowel disease may be complicated
early after the diagnosis22,23. More recent studies indi-
cate also the role of the genetic risk factors on the prog-
nosis of CD and IBD and the potential influence of early
introduction of immunomodulatory or biologic therapy,
in slowing down disease progression and altering the
natural history of IBD13,24,25.
Discussion on complications
As already mentioned, it is well known that patients
with CD are more prone to develop late intestinal compli-
cations, either as stricturing, or penetrating, or as their
combinations. This is why the majority of patients with
CD need surgery within 10 years of diagnosis14,26. Predis-
position to these complications is due to deep inflamma-
tion, tending to affect the whole wall thickness. Stric-
tures and luminal opstructions (clinical correlates of
ileus) may be either on the basis of inflammatory mass
(including abscess formation), or fibrotic tissue forma-
tion. In fact, stricture and fistula are often found in prox-
imity of one another, as fistula develops to decompress
the lumen at the site of stricture27. Our results are in line
with these pathologic features, indicating significantly
higher participation of intestinal complications, in pa-
tients with CD, than in those with UC. These registered
complications include: intestinal perforation (CD/UC,
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TABLE 7
THE MONTREAL’S CLASSIFICATION OF INFLAMMATORY BOWEL DISEASE MONTREAL CLASSIFICATION OF THE EXTENT
OF ULCERATIVE COLITIS
Extent Anatomy
E1 (Ulcerative proctitis) Involvement limited to the rectum (that is, proximal extent of inflammation is distal to
the rectosigmoid junction)
E2 (Left sided UC – distal UC) Involvement limited to a proportion of the colorectum distal to the splenic flexure
E3 (Extensive UC – pancolitis) Involvement extends proximal to the splenic flexure
Montreal classification of severity of ulcerative colitis
Severity Definition
S0 – Clinical remission Asymptomatic
S1 – Mild UC Passage of four or fewer stools/day (with or without blood), absence of any systemic
illness, and normal inflammatory markers (Erythrocyte Sedimentation Rate)
S2 – Moderate UC Passage of more than four stools per day but with minimal signs of systemic toxicity
S3 – Severe UC Passage of at least six bloody stools daily, pulse rate of at least 90 beats per minute,
temperature of at least 37.5 °C, Haemoglobin of less than 10.5 g/100 mL, and Erythro-
cyte Sedimentation Rate of at least 30 mm/h
Montreal classsification for Crohn’s disease
Age at diagnosis A1 – below 16 y
A2 – between 17 and 40 y
A3 – above 40 y
Location L1 – ileal
L2 – colonic
L3 – ileocolonic
L4 – isolated upper disease (a modifier that can be added to L1-L3 when concomitant
upper disease is present)
Behaviour B1 – non-stricturing, non-penetrating
B2 – stricturing
B3 – penetrating
P – perineal disease modifier (is added to B1-B3 when concomitant perineal disease is
present)
9.7%/0.8%), fistula (CD/UC, 22.6%/0.8%), abscess (CD/
UC, 29.0%/0.8%) and ileus (CD/UC, 25.8%/0.8%) (Table
3). Although these results do not indicate the proportion
of patients who needed the surgical intervention, data
yet allow some comparisons. For example, studies from
Olmsted County, Minnesota, USA, reported that 41% of
patients with CD underwent at least one resection, and
57% of patients – at least one operative procedure28,29.
It is well known that extraintestinal manifestations
are common in both UC and CD3,30. Some of these mani-
festations can be prescribed to nutritional and metabolic
disturbances, secondary to chronic intestinal inflamma-
tory process, such as, e.g., gallstones, or renal stones,
osteoporotic, fatty liver, or thromboembolic disor-
ders3,31,32. In considering causes, of note is also the im-
pact of corticosteroid therapy. As causes of other extra-
intestinal manifestations, including primary sclerosing
cholangitis, ankylosing spondylitis, iritis/uveitis, pyoder-
ma gangrenosum, erythema nodosum and demyelinating
disorder – cross-reacting autoantibodies have been pro-
posed33. According to the results of the Manitoba study
(Canada), as much as 6.2% of patients with IBD devel-
oped some of these manifestations, 10 years or more af-
ter the diagnosis34. In the IBSEN cohort study, the over-
all prevalence of spondyloarthropathies, in patients with
CD, was 26%, while 6% of patients had ankylosing spon-
dylitis (73% HLA-B27 positive)35. In our sample, patients
with CD had higher (although of a marginal significance)
proportion of cases with immunologicaly mediated extra-
intestinal disorders, ankylosing spondylitis and erythe-
ma nodosum, than patients with UC. This seems logical,
as CD, in contrast to UC, is considered as autoimmune
disorder36. Relatively high percentage of patients with
ankylosing spondylitis (12.9%) may be the artefat of the
small sample, or of imprecise diagnosis, as cases with
non-specific spondyloarthropathies might have also been
taken into account.
Conclusions / Limitations
This analysis of the clinical characteristics of the co-
hort population, diagnosed with IBD, was performed as
the part of the epidemiologic study, aimed at assessing
the incidence and prevalence of UC and CD, in Vuko-
varsko-Srijemska County, Croatia. Patients were inter-
viewed retrospectively, by using standardised protocols,
on age and symptoms at the time of diagnosis, intestinal
and extraintestinal complications and the localization
and the extent of disease. Based on these latter peaces of
information, phenotypes, defined by using the Montral`s
classification, were determined accordingly. Since data
are used in a cross-sectional and retrospective manner,
many important, timely-based associations are missing.
Based on this analysis, it is not possible, for example, to
determine types of complications in relation to disease
duration, or the time-dependent and the treatment-de-
pendent evolution of disease. Conclusions on the impact
of changes in environmental risk factors and demogra-
phic features, on the natural course and spreading of
IBD, are also not possible to make. However, this study
might be the starting position in developing the national
register of patients with IBD, necessary if someone
wants to continuously follow-up changes in frequency
and characteristics of IBD. Only such, dynamical ap-
proach, will allow causal relationships, essential for the
purpose of designing advanced therapeutic options.
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KLINI^KE ZNA^AJKE KRONI^NIH UPALNIH BOLESTI CRIJEVA – RETROSPEKTIVNA
POPULACIJSKA KOHORTNA STUDIJA VUKOVARSKO-SRIJEMSKE @UPANIJE, HRVATSKA, 2010.
S A @ E T A K
Klini~ke zna~ajke kohortne skupine od 150 pacijenata, s upalnim bolestima crijeva, uklju~uju}i ulcerozni kolitis
(UC) i Cronovu bolest (CB), iz Vukovarsko-srijemske `upanije, Hrvatska, su retrospektivno ispitivane. Najva`nije kli-
ni~ke zna~ajke pacijenata s ulceroznim kolitisom su bile u~estale krvave i sluzave stolice, a u pacijenata s CB, to su bili
vru}ica, anemija i ja~i gubitak tjelesne mase, {to je dijelom odraz i du`eg trajanja simptoma prije vremena dijagnoze, u
pacijenata s CB. Vode}e lokalizacije bolesti, u pacijenata s UC, su bile rektum i lijevi kolon te anorektum, dok je najza-
stupljeniji fenotip, u pacijenata s CB, odgovarao mla|oj, odrasloj dobi pri postavljanju dijagnoze, lokalizaciji bolesti u
ileokolonu, te tipu bolesti karakteriziranoj sklono{}u ka razvoju crijevnih striktura. Intestinalne komplikacije, per-
foracija, fistula, absces i ileus, su bile u~estalije u pacijenata s CB. Od ekstraintestinalnih komplikacija, samo su ankilo-
ziraju}i spondilitis i nodozni eritem i to samo grani~no zna~ajno vi{e bili zastupljeni u pacijenata s CB. Glavni nedosta-
tak ove studije je izostanak ispitivanja povezanosti te vremenski-ovisne projekcije bolesti.
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